








Cite this: *Chem. Commun.*, 2020, 56, 7949

Received 24th April 2020,
Accepted 2nd June 2020

DOI: 10.1039/d0cc02976a

rsc.li/chemcomm

Synthesis of protected 3-aminopiperidine and 3-aminoazepane derivatives using enzyme cascades†

Grayson J. Ford, Nico Kress, Ashley P. Matthey,  Lorna J. Hepworth, Christopher R. Baldwin, James R. Marshall, Lisa S. Seibt,  Min Huang, William R. Birmingham,  Nicholas J. Turner  and Sabine L. Flitsch *

Multi-enzyme cascades utilising variants of galactose oxidase and imine reductase led to the successful conversion of *N*-Cbz-protected L-ornithinol and L-lysinoL to L-3-*N*-Cbz-aminopiperidine and L-3-*N*-Cbz-aminoazepane respectively, in up to 54% isolated yield. Streamlining the reactions into one-pot prevented potential racemisation of key labile intermediates and led to products with high enantiopurity.

Chiral amine moieties are present in many of the most valuable pharmaceutical compounds,^{1,2} with cyclic diamines in particular often used as semi-rigid bifunctional linkers in medicinal chemistry. Hence there is a demand for efficient, stereoselective synthesis strategies of diamines from easily accessible starting materials, preferentially in their semi-protected form to allow direct application in the manufacture of pharmaceutical intermediates. Recent biocatalytic methodologies have proven to be very successful in the design of alternative efficient and sustainable processes in the synthesis of chiral amines, underpinned by an increasing interest in their industrial application.³ In this regard, we were interested in the chiral enzymatic synthesis of semi-protected 3-aminopiperidines **7** and 3-aminoazepanes **8**, being core structures in many valuable pharmaceutical drugs such as alogliptin and besifloxacin.^{4,5}

Current synthetic methods towards 3-aminopiperidines and 3-aminoazepanes encompass various approaches, including Curtius and Hofmann rearrangements, hydrogenation of 3-aminopyridine or the cyclisation of α -amino acids.^{6–8} Although these routes are well established, they often lack chiral control and the use of expensive and toxic reagents can hinder their wider industrial application. The particular challenge of chiral 3-aminoazepanes such as **8** was recently addressed by Feng *et al.* using a transaminase-based biocatalytic synthesis of

3-aminoazepane from ketone precursors.⁹ An attractive strategy is the combination of biocatalysts in telescoped enzymatic cascades resembling biosynthetic pathways to generate unnatural compounds.^{10–13}

When targeting **7** and **8**, the challenge was to find enzymes that could tolerate bulky unnatural protection groups such as carboxybenzyl (Cbz) groups, which are needed for subsequent coupling chemistries. Based on our previous expertise in the application of galactose oxidase (GOase)^{14–17} and imine reductase (IRE)^{18–22} biocatalysts, a multi-enzymatic cascade towards amino-piperidine and amino azepanes was designed. This streamlined approach uses readily available amino alcohols such as **1a–c** and **2a–c** as substrates, (Fig. 1), which were directly accessible by chemical synthesis from natural amino acids L-ornithine and L-lysine (ESI†).

The enzymatic cascade would then proceed by initial oxidation of amino alcohols **1** and **2** to the respective amino aldehydes




Fig. 1 Enzyme cascade for the synthesis of L-3-*N*-aminopiperidines and L-3-*N*-aminoazepanes using a combination of galactose oxidase (GOase) and imine reductase (IRE) enzymes.

Department of Chemistry, Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.

E-mail: Sabine.flitsch@manchester.ac.uk

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0cc02976a



3 or **4** by GOase, followed by spontaneous formation of cyclic imine intermediates **5** or **6** that would finally be reduced by an IRED to generate the desired enantiopure products **7** and **8**.¹⁷ Both individual enzymatic reactions have already shown promise in industrial applications.^{23,24}

The proposed strategy presented multiple challenges: the α -amino aldehyde intermediates from substrates **1a** and **2a** would be predicted to be very unstable in a biotransformation. Considering the need for selective protection of the target compounds for subsequent chemical coupling reactions in API synthesis anyway, Boc- and Cbz-protected starting materials **1b-c** and **2b-c** were investigated as leading to reagents that are more valuable. However, the use of monoprotected substrates would require the tolerance of the chosen biocatalysts towards bulky hydrophobic protecting groups. To minimize side-reactions, purified enzymes rather than whole cells or enzyme lysates were used.

For the first step of the enzyme cascade, suitable recombinant GOase variants **F₂** and **M₃₋₅** were tested for the oxidation of amino alcohols **1a-c** and **2a-c** (ESI[†]).^{14,17} An initial activity screen showed that the Cbz-protected amino alcohol derivatives **1c** and **2c** gave highest initial activity, whilst unprotected and Boc-protected derivatives **1a-b** and **2a-b** were not well accepted as substrates (ESI[†]). The poor results for the unprotected substrates **1a** and **2a** might be due to instability of the amino aldehyde intermediates and problems with amino alcohol functionality, which can result in potential chelation of the active copper center in GOase.²⁵

Given that Cbz-protected substrates **1c** and **2c** demonstrated good activity, a colorimetric HRP-ABTS assay was used to determine kinetic constants comparing the two GOase mutants **F₂** and **M₃₋₅** (Table 1).²⁶ Both mutants showed overall comparable activity, *L*-lysine derivative **2c** appeared to be preferred over *L*-ornithine **1c**, with significant higher catalytic efficiency, particularly for the **M₃₋₅** variant.

Encouraged by these results, the GOase variants were tested in combination with an IRED panel in a one-pot reaction, thus avoiding the need to isolate potentially unstable aldehyde/imine intermediates. Five IREDs were selected from available libraries for the first screen: AdRedAm, IR-23, IR-49, IR-102 and IR-110. AdRedAm was chosen because of its broad substrate range, whereas the other four IREDs have been previously shown to accept the azepane scaffold.^{20,27}

Previous studies directed the reaction design for the one-pot *in vitro* GOase-IRED cascade, which included HRP for activation




Fig. 2 Result of activity screening for the synthesis of 3-*N*-Cbz-aminopiperidine **7** and 3-*N*-Cbz-aminoazepane **8** comparing 2 GOases and 5 IREDs. Reactions were performed with 3 mM substrate in NaPi buffer (pH 7.5) at 30 °C and 200 rpm for 16 h. The resulting analytical yields were determined by GC-FID and are given as colour-coded ranges.

of GOase, catalase for H₂O₂ decomposition, while NADP⁺ in combination with glucose dehydrogenase (GDH) and glucose was added as a cofactor recycling system to ensure electron supply for the IRED reaction.^{26,28} Considering previously optimized reaction conditions for both GOase and IRED, initial analytical scale reactions were performed in phosphate buffer at pH 7.5 and 30 °C for 16 h.^{26,29}

Chromatographic analysis of the reaction mixtures showed only trace amounts of products for **1a** and **2a**, and so were not investigated further (ESI[†]). The Boc-protected substrates **1b** and **2b** showed no detectable activity, but we were pleased to observe a range of potential GOase-IRED combinations to be active towards the Cbz-protected substrates **1c** and **2c** (Fig. 2 and ESI[†]). We were surprised to find a marked preference for the *L*-lysine substrate **2c** over the *L*-ornithine substrate **1c**, considering that the azepane imine intermediate would be expected to be less readily formed than the corresponding piperidine imine. For both substrates, the GOase **M₃₋₅** variant performed considerably better than **F₂**, which is in agreement with previously reported amino alcohol conversions.¹⁷ The IRED preference was found to be strongly substrate dependent, with AdRedAm performing best in the case of the piperidine product **7**, while IR-49 was optimal for azepane **8** synthesis.

A set of reaction optimizations were performed for both cascades to give products **7** and **8**, including pH, reaction temperature, enzyme loading and substrate concentration (ESI[†]). Each parameter was altered individually while other parameters stayed constant for both. The cascade was screened over a range of reaction pHs (6–8). An optimal pH of 8 was determined for the enzyme cascades, resulting in higher product yields for both when compared to a lower reaction pH, following general previous trends for both enzymes used.^{26,29}

Table 1 Kinetic constants K_m and k_{cat} for oxidations of *N*- α -Cbz-ornithine **1c** and *N*- α -Cbz-lysine **2c** using GOase variants **M₃₋₅** and **F₂**

Substrate-GOase	K_m [mM]	V_{max} [U mg ⁻¹]	k_{cat} [s ⁻¹]	K_{cat}/K_m [mM s ⁻¹]
1c-F₂	70.7 \pm 7.2	0.83 \pm 0.09	0.9 \pm 0.1	0.013
1c-M₃₋₅	47 \pm 15	0.77 \pm 0.22	0.87 \pm 0.25	0.019
2c-F₂	70.5 \pm 2.2	1.74 \pm 0.05	1.97 \pm 0.06	0.028
2c-M₃₋₅	40.5 \pm 7.3	2.29 \pm 0.34	2.57 \pm 0.42	0.063

Conditions: ABTS-HRP coupled assay in NaPi (100 mM, pH 7.4) with substrates **1c** and **2c** at various concentrations, λ = 420 nm, 25 °C (ESI).



Increasing reaction temperatures above 30 °C resulted in lower conversions, suggesting deactivation of the enzyme at these temperatures. Increasing IRED concentration showed minimal variation in the yield, but increasing the GOase concentration improved product yield, confirming that the IRED does not appear to be rate limiting. It was also noted that conversions for the transformation did not increase further when more than 0.5 mg ml⁻¹ GOase was used for the transformation of **2c** to product **8**, but did increase up to 1 mg ml⁻¹ for the transformation of **1c** to product **7**. Combined with the initial kinetic screening results, this further confirms the higher affinity GOase M₃₋₅ has for substrate **2c** over **1c**.

Given that the GOase is the gatekeeper for the cascade, molecular docking studies were performed to better understand substrate specificity. F₂ and M₃₋₅ models were created based on the reported E₁ variant structure (PDB 2WQ8). **1c** and **2c** were used as ligands for the docking simulation into the two GOase mutants. The displayed binding modes in Fig. 3 represent the catalytic binding modes with the highest calculated binding affinity. For catalytic binding, the free copper binding site needs to be occupied by the hydroxy group that is to be oxidized in the radical-based GOase mechanism.³⁰ In the E₁ crystal structure, a co-crystallized acetate binds the copper in 2.3 Å distance, which is closely mimicked by the calculated binding of **1c** and **2c** to M₃₋₅. In contrast, more than 1 Å greater distances are calculated for binding to F₂, supporting the kinetic data. Interestingly, the ligands adopt two opposing binding modes with respect to the Cbz phenyl group.




Fig. 3 Molecular docking (AutoDock Vina as implemented in YASARA) of *N*-α-Cbz-ornithinol **1c** and *N*-α-Cbz-lysine **2c** in GOase variants M₃₋₅ and F₂ modelled based on the E₁ variant crystal structure (PDB 2WQ8). Substrate (cyan) conformations positioning the target hydroxyl group towards the copper centre (dark orange) are depicted with the respective O–Cu distance in red. Substrate-interacting active site amino acids are highlighted (purple) indicating residues altered in between the GOase variants (green). Selected substrate–receptor interactions are highlighted (yellow).

While the phenyl group binds atop P463 in M₃₋₅, it is bound above F290 in F₂ allowing for stronger π–π stacking. Two of the mutational differences between M₃₋₅ and F₂ seem to be mainly responsible for the altered interaction networks in substrate binding being M/K330 and T/E406. K330 in F₂ seems to cause a displaced hydroxy orientation, while E406 is a potential salt bridge partner for the terminal charged amino group. Comparing **1c** and **2c**, the extended length of the lysinol allows for a strong salt bridge formation with E195 and E406 in M₃₋₅ and F₂ respectively; which is less pronounced for the shorter ornithinol, serving as a potential structural explanation for the observed preference for lysinol.

Using optimized reaction conditions of higher GOase concentrations and a reaction pH of 8, the biotransformations of **1c** and **2c** were scaled up to a final volume of 90 mL. For substrate **1c** (3 mM), GOase M₃₋₅ and AdRedAm were used (1 mg ml⁻¹ and 0.25 mg ml⁻¹ respectively). Protein precipitation of AdRedAm was observed after 1–3 h of the reaction in contrast to the analytical scale reactions (ESI[†]). Nonetheless, we were able to extract and isolate product **7** in 16% yield (10 mg) using a simple acid–base wash. For substrate **2c**, we were able to use less enzyme with 0.5 mg ml⁻¹ M₃₋₅ and 0.25 mg ml⁻¹ IR-49. Under these reaction conditions, no precipitate formed within the 48 h of reaction time and following the same workup protocol as before, a yield of 54% (36 mg) product **8** was isolated and characterized from the reaction.

The enantiopurity of **7** and **8** was determined using chiral normal phase HPLC analysis, comparing the products from the scaled-up biotransformations, with authentic and synthesized standards (ESI[†]). Chromatograms showed the presence of only one enantiomer per reaction, confirming preservation of the initial amino acid-derived L-configuration.

In conclusion, we showed that industrially relevant enzymes, GOase and IRED can be combined in a novel one-pot enzymatic cascade to synthesize enantiopure Cbz-protected L-3-aminopiperidine **7** and L-3-aminoazepane **8** products from amino alcohols derived from bio-renewable amino acids as a green feedstock under ambient conditions. The strategy allows for directly generating selectively Cbz protected targets, that are compatible for subsequent incorporation into chemical processes. The lack of racemization demonstrates the advantage of using one-pot streamlined cascades.

We kindly acknowledge financial support from the European Research Council (788231-ProgrES-ERC-2017-ADG to SLF; BIO-H-BORROW: Grant No. 742987 to NJT); EU (CarboMet 737395) BBSRC (BB/M027791/1; BB/M02903411; BB/M028836/1). J. R. M. acknowledges the Industrial Biotechnology Innovation Centre (IBioIC) and BBSRC funding through a CASE studentship with Prozomix Ltd. W. R. B. gratefully acknowledges the Biotechnology and Biological Sciences Research Council (BBSRC) for the award of a Discovery Fellowship (BB/S010459/1).

Conflicts of interest

There are no conflicts to declare.



Notes and references

- 1 M. Breuer, K. Ditrach, T. Habicher, B. Hauer, M. Keßeler, R. Stürmer and T. Zelinski, *Angew. Chem., Int. Ed.*, 2004, **43**, 788–824.
- 2 D. Ghislieri and N. J. Turner, *Top. Catal.*, 2014, **57**, 284–300.
- 3 M. Schober, C. MacDermaid, A. A. Ollis, S. Chang, D. Khan, J. Hosford, J. Latham, L. A. F. Ihnken, M. J. B. Brown, D. Fuerst, M. J. Sanganee and G. D. Roiban, *Nat. Catal.*, 2019, **2**, 909–915.
- 4 J. Feng, Z. Zhang, M. B. Wallace, J. A. Stafford, S. W. Kaldor, D. B. Kassel, M. Navre, L. Shi, R. J. Skene, T. Asakawa, K. Takeuchi, R. Xu, D. R. Webb and S. L. Gwaltney, *J. Med. Chem.*, 2007, **50**, 2297–2300.
- 5 W. Haas, C. M. Pillar, G. E. Zurenko, J. C. Lee, L. S. Brunner and T. W. Morris, *Antimicrob. Agents Chemother.*, 2009, **53**, 3552–3560.
- 6 H. Nienburg, *Ber. Dtsch. Chem. Ges. A/B*, 1937, **70**, 635–638.
- 7 M. Yamada, S. Hirano, R. Tsuruoka and M. Yamano, WO 2008/102720 A1, 2008.
- 8 K. Oskada, T. Ikariya, M. Saburi and S. Yoshikawa, *Chem. Lett.*, 1981, 1691–1694.
- 9 Y. Feng, Z. Luo, G. Sun, M. Chen, J. Lai, W. Lin, S. Goldmann, L. Zhang and Z. Wang, *Org. Process Res. Dev.*, 2017, **21**, 648–654.
- 10 S. P. France, L. J. Hepworth, N. J. Turner and S. L. Flitsch, *ACS Catal.*, 2017, **7**, 710–724.
- 11 J. H. Schrittwieser, S. Velikogne, M. Hall and W. Kroutil, *Chem. Rev.*, 2018, **118**, 270–348.
- 12 J. I. Ramsden, R. S. Heath, S. R. Derrington, S. L. Montgomery, J. Mangas-Sanchez, K. R. Mulholland and N. J. Turner, *J. Am. Chem. Soc.*, 2019, **141**, 1201–1206.
- 13 C. Martin, M. Trajkovic and M. W. Fraaije, *Angew. Chem., Int. Ed.*, 2020, **59**, 4869–4872.
- 14 L. Sun, I. P. Petrounia, M. Yagasaki, G. Bandara and F. H. Arnold, *Protein Eng., Des. Sel.*, 2001, **14**, 699–704.
- 15 J. B. Rannes, A. Ioannou, S. C. Willies, G. Grogan, C. Behrens, S. L. Flitsch and N. J. Turner, *J. Am. Chem. Soc.*, 2011, **133**, 8436–8439.
- 16 F. Escalettes and N. J. Turner, *ChemBioChem*, 2008, **9**, 857–860.
- 17 A. J. Carnell, A. R. Frazer, S. M. McKenna, S. Herter, S. Leimkühler and N. J. Turner, *ChemCatChem*, 2015, **7**, 2313–2317.
- 18 K. Mitsukura, M. Suzuki, K. Tada, T. Yoshida and T. Nagasawa, *Org. Biomol. Chem.*, 2010, **8**, 4533–4535.
- 19 M. Lenz, N. Borlinghaus, L. Weinmann and B. M. Nestl, *World J. Microbiol. Biotechnol.*, 2017, **33**, 199.
- 20 W. Zawodny, S. L. Montgomery, J. R. Marshall, J. D. Finnigan, N. J. Turner and J. Clayden, *J. Am. Chem. Soc.*, 2018, **140**, 17872–17877.
- 21 P. Matzel, M. Gand and M. Höhne, *Green Chem.*, 2017, **19**, 385–389.
- 22 A. Al-Shameri, N. Borlinghaus, L. Weinmann, P. N. Scheller, B. M. Nestl and L. Lauterbach, *Green Chem.*, 2019, **21**, 1396–1400.
- 23 M. A. Huffman, A. Fryszkowska, O. Alvizo, M. Borra-Garske, K. R. Campos, K. A. Canada, P. N. Devine, D. Duan, J. H. Forstater, S. T. Grosser, H. M. Halsey, G. J. Hughes, J. Jo, L. A. Joyce, J. N. Kolev, J. Liang, K. M. Maloney, B. F. Mann, N. M. Marshall, M. McLaughlin, J. C. Moore, G. S. Murphy, C. C. Nawrat, J. Nazor, S. Novick, N. R. Patel, A. Rodriguez-Granillo, S. A. Robaire, E. Sherer, M. D. Truppo, A. M. Whittaker, D. Verma, L. Xiao, Y. Xu and H. Yang, *Science*, 2019, **366**, 1255–1259.
- 24 M. Schober, C. MacDermaid, A. A. Ollis, S. Chang, D. Khan, J. Hosford, J. Latham, L. A. F. Ihnken, M. J. B. Brown, D. Fuerst, M. J. Sanganee and G. D. Roiban, *Nat. Catal.*, 2019, **2**, 909–915.
- 25 N. Kaewchangwat, S. Dueansawang, G. Tumcharern and K. Suttisintong, *J. Agric. Food Chem.*, 2017, **65**, 9828–9837.
- 26 A. Toftgaard Pedersen, W. R. Birmingham, G. Rehn, S. J. Charnock, N. J. Turner and J. M. Woodley, *Org. Process Res. Dev.*, 2015, **19**, 1580–1589.
- 27 G. A. Aleku, S. P. France, H. Man, J. Mangas-Sanchez, S. L. Montgomery, M. Sharma, F. Leipold, S. Hussain, G. Grogan and N. J. Turner, *Nat. Chem.*, 2017, **9**, 961–969.
- 28 C. H. Wong, D. G. Drueckhammer and H. M. Sweers, *J. Am. Chem. Soc.*, 1985, **107**, 4028–4031.
- 29 J. Mangas-Sanchez, S. P. France, S. L. Montgomery, G. A. Aleku, H. Man, M. Sharma, J. I. Ramsden, G. Grogan and N. J. Turner, *Curr. Opin. Chem. Biol.*, 2017, **37**, 19–25.
- 30 R. M. Wachter and B. P. Branchaud, *J. Am. Chem. Soc.*, 1996, **118**, 2782–2789.

